Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy

American Journal of Surgical Pathology

Volumn 33, Issue 11, 2009, Pages 1615-1623

  Grin, Andrea ^a   O'Malley, Frances P ^a   Mulligan, Anna Marie ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Core biopsy; Cytokeratin 5; Estrogen receptor; Papillary lesion

Indexed keywords

CYTOKERATIN 5; ESTROGEN RECEPTOR;

ARTICLE; BREAST LESION; CELL PROLIFERATION; CONTROLLED STUDY; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PERCUTANEOUS BIOPSY; PROTEIN EXPRESSION;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, PAPILLARY; CELL COUNT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; KERATIN-5; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 70350451533     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181aec446     Document Type: Article

References (34)

1. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32:513-523.
2. Agoff SN, Lawton TJ. Papillary lesions of the breast with and without atypical ductal hyperplasia: can we accurately predict benign behavior from core needle biopsy? Am J Clin Pathol. 2004; 122:440-443.
3. Alonso-Bartolome P, Vega-Bolivar A, Torres-Tabanera M, et al. Sonographically guided 11-G directional vacuum-assisted breast biopsy as an alternative to surgical excision: utility and cost study in probably benign lesions. Acta Radiol. 2004;45:390-396.
4. Bhargava R, Beriwal S, McManus K, et al. CK5 is more sensitive than CK5/6 in identifying the ''basal-like'' phenotype of breast carcinoma. Am J Clin Pathol. 2008;130:724-730.
5. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol. 2001;195:415-421.
6. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol. 2002;198:458-467.
7. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19:617-621.
8. Carder PJ, Khan T, Burrows P, et al. Large volume ''mammotome'' biopsy may reduce the need for diagnostic surgery in papillary lesions of the breast. J Clin Pathol. 2008;61:928-933.
9. Douglas-Jones A, Shah V, Morgan J, et al. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology. 2005;47:202-208.
10. Fine RE, Boyd BA, Whitworth PW, et al. Percutaneous removal of benign breast masses using a vacuum-assisted hand-held device with ultrasound guidance. Am J Surg. 2002;184:332-336.
11. Ichihara S, Fujimoto T, Hashimoto K, et al. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Pathol Int. 2007;57: 126-132.
12. Ivan D, Selinko V, Sahin AA, et al. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy. Mod Pathol. 2004;17:165-171. (Pubitemid 41656512)
13. Kim MJ, Kim EK, Park SY, et al. Imaging-histologic discordance at sonographically guided percutaneous biopsy of breast lesions. Eur J Radiol. 2008;65:163-169.
14. Krainick-Strobel U, Huber B, Majer I, et al. Complete extirpation of benign breast lesions with an ultrasound-guided vacuum biopsy system. Ultrasound Obstet Gynecol. 2007;29:342-346.
15. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch. 2003;442:548-554.
16. Liberman L, Bracero N, Vuolo MA, et al. Percutaneous large-core biopsy of papillary breast lesions. AJR Am J Roentgenol. 1999;172: 331-337.
17. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38: 197-204.
18. Mathew J, Crawford DJ, Lwin M, et al. Ultrasound-guided, vacuum-assisted excision in the diagnosis and treatment of clinically benign breast lesions. Ann R Coll Surg Engl. 2007;89:494-496.
19. Mercado CL, Hamele-Bena D, Singer C, et al. Papillary lesions of the breast: evaluation with stereotactic directional vacuum-assisted biopsy. Radiology. 2001;221:650-655.
20. NHS. Image-guided vacuum-assisted excision biopsy of benign breast lesions. Febuary 2006. Available at: www.nice.org.uk/ nicemedia/pdf/ip/ IPG156guidance.pdf. Accessed March 29, 2009.
21. Nofech-Mozes S, Holloway C, Hanna W. The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies. Int J Surg Pathol. 2008;16:399-406.
22. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008;52:3-10.
23. Otterbach F, Bankfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37:232-240.
24. Rabban JT, Koerner FC, Lerwill MF. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol. 2006;37:787-793.
25. Raju U, Crissman JD, Zarbo RJ, et al. Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast. Am J Surg Pathol. 1990;14:939-947.
26. Renshaw AA, Derhagopian RP, Tizol-Blanco DM, et al. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol. 2004;122: 217-221.
27. Rosen EL, Bentley RC, Baker JA, et al. Imaging-guided core needle biopsy of papillary lesions of the breast. AJR Am J Roentgenol. 2002;179:1185-1192.
28. Shah VI, Flowers CI, Douglas-Jones AG, et al. Immunohisto-chemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens. Histopathology. 2006;48:683-691.
29. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol. 2005; 29:734-746.
30. Sydnor MK, Wilson JD, Hijaz TA, et al. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology. 2007;242:58-62.
31. Tan PH, Aw MY, Yip G, et al. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol. 2005;29: 625-632.
32. Tennant SL, Evans A, Hamilton LJ, et al. Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3)-an alternative to surgery in selected cases. Breast. 2008;17:546-549.
33. Tse GM, Tan PH, Moriya T. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol. 2009;62:407-413.
34. Valdes EK, Feldman SM, Boolbol SK. Papillary lesions: a review of the literature. Ann Surg Oncol. 2007;14:1009-1013